Neurocrine expands into metabolic diseases with $2.9 billion Soleno buyout
Neurocrine Biosciences will acquire rare-disease drugmaker Soleno Therapeutics for $2.9 billion in cash, the companies said on Monday, marking the neuroscience-
April 06, 2026
Europe's tech 'liberation day'? Computer says not yet
Australia's lower house passes bill for biggest overhaul of taxes in decades
A ceasefire too far for markets
Wembanyama scores 26 but struggles from field in NBA Finals debut as Spurs fall to Knicks in Game 1
Treasury Wine bets on Penfolds-led luxury push to revive fortunes
California man charged with bringing explosives to Sacramento airport after repeatedly calling FBI tip line